Combined measurement of fasting plasma glucose and HbA1c is effective for the prediction of type 2 diabetes: The Kansai Healthcare Study
- Kyoko Kogawa Sato, M.D., PhD. (ksato{at}med.osaka-cu.ac.jp),
- Tomoshige Hayashi, M.D., PhD.,
- Nobuko Harita, M.D.,
- Takeshi Yoneda, M.D.,
- Yoshiko Nakamura, M.D., PhD.,
- Ginji Endo, M.D., PhD. and
- Hiroshi Kambe, M.D.
- Department of Preventive Medicine and Environmental Health, Osaka City University Graduate School of Medicine, Osaka, Japan (K.K.S., T.H., N.H., T.Y., G.E., H.K.) and Kansai Health Administration Center, Nippon Telegraph and Telephone West Corporation (Y.N., H.K.)
Abstract
Objective: We prospectively assessed whether the combined measurements of fasting plasma glucose (FPG) and HbA1c were effective to predict type 2 diabetes.
Research design and methods: Study participants included 6736 nondiabetic Japanese men aged 40-55 years. Type 2 diabetes was diagnosed if FPG was ≥126 mg/dL or if participants were treated by oral antidiabetic agent or insulin. The models including FPG, HbA1c, and both were compared using the area under the receiver operator characteristic (AUROC) curves.
Results: During the 4-year follow-up period, we confirmed 659 cases. In multivariate analysis, both FPG and HbA1c were independently associated with the risk of type 2 diabetes. The model including both FPG and HbA1c had a greater AUROC curve than that including FPG alone (0.853 vs. 0.818, p<0.001) or HbA1c alone (0.853 vs. 0.771, p <0.001).
Conclusions: The combined measurement of FPG and HbA1c was effective to predict type 2 diabetes.
Footnotes
-
- Received September 4, 2008.
- Accepted January 1, 2009.
- Copyright © American Diabetes Association
